Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
Erstveröffentlichung
2021
Wissenschaftlicher Artikel
Published in
Haematologica ; 106 (2021), 12. - S. 3240-3244. - ISSN 0390-6078